A5027510418- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cardiac Imaging and Diagnostics
- Parathyroid Disorders and Treatments
- Sarcoidosis and Beryllium Toxicity Research
- Transplantation: Methods and Outcomes
- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Cardiac Structural Anomalies and Repair
- Advanced MRI Techniques and Applications
- Mechanical Circulatory Support Devices
- Cardiomyopathy and Myosin Studies
- Medical Imaging Techniques and Applications
- Advanced X-ray and CT Imaging
- Renal Transplantation Outcomes and Treatments
- Peptidase Inhibition and Analysis
- Cardiac pacing and defibrillation studies
- Medical Imaging and Pathology Studies
- Eosinophilic Disorders and Syndromes
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Cardiac electrophysiology and arrhythmias
- Cardiovascular Disease and Adiposity
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Viral Infections and Immunology Research
- COVID-19 and healthcare impacts
- Cardiac Arrhythmias and Treatments
University of Missouri–Kansas City
2018-2025
Saint Luke's Hospital
2018-2025
American Heart Institute
2023-2024
Cleveland Clinic
2014-2023
Saint Luke's Health System
2019-2023
Soochow University
2023
Intermountain Healthcare
2023
University of Michigan
2023
Pfizer (United States)
2023
University of Vermont
2023
Background: In patients with transthyretin amyloid cardiomyopathy, tafamidis reduces all-cause mortality and cardiovascular hospitalizations slows decline in quality of life compared placebo. May 2019, received expedited approval from the US Food Drug Administration as a breakthrough drug for rare disease. However, at $225 000 per year, it is most expensive ever launched United States, its long-term cost-effectiveness budget impact are uncertain. We therefore aimed to estimate potential...
Positron emission tomography (PET) myocardial perfusion imaging (MPI) can non-invasively measure blood flow reserve (MBFR). We aimed to examine whether MBFR identifies patients with a survival benefit after revascularization, helping guide post-test management.We examined all-cause mortality in 12 594 consecutive undergoing Rb82 rest/stress PET MPI from January 2010 December 2016, excluding those cardiomyopathy, prior coronary artery bypass surgery (CABG), and missing MBFR. Myocardial was...
<h3>Objective</h3> Cardiac amyloidosis (CA) is a rapidly progressive disease that portends poor prognosis. Our objective was to evaluate the prognostic impact of relative regional strain ratio (RRSR, measure apical sparing longitudinal (LS)) in CA. <h3>Methods</h3> This retrospective study evaluating 97 patients with CA from 2004 2013. Patients were included if they met criteria for based on endomyocardial biopsy or advanced imaging coupled either extracardiac genetic analysis. Baseline...
Prior studies with single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) have shown a survival benefit early revascularization in patients >10% to 12.5% ischemic myocardium. The relationship among positron (PET)–derived extent of ischemia, revascularization, and is unknown. purpose this study was evaluate the association percent ischemia on PET MPI, survival. A total 16,029 unique consecutive who were undergoing Rubidium-82 rest-stress MPI from 2010 2016...
Coronary artery calcium score (CACS) is an anatomic measure of calcified atherosclerosis. Myocardial perfusion defects and reduced myocardial blood flow reserve (MBFR) are physiological measures ischemia coronary circulatory health. We aimed to assess the relative prognostic importance MBFR, defects, CACS in patients with suspected disease.A total 5983 consecutive without known history disease or cardiomyopathy, who underwent a 82Rb positron emission tomography imaging between 2010 2016,...
Chronic kidney disease (CKD) is common among patients with amyloid cardiomyopathy. Tafamidis was approved for the treatment of transthyretin cardiomyopathy (ATTR-CM) based on findings from ATTR-ACT (Safety and Efficacy in Patients With Transthyretin Cardiomyopathy).
Transthyretin (ATTR) amyloidosis is an under-recognized, progressive disease manifesting as cardiomyopathy and/or polyneuropathy. Diflunisal, a nonsteroidal anti-inflammatory drug (NSAID), has demonstrated transthyretin stabilization in vitro and slowing of polyneuropathy progression the hereditary ATTR subtype (ATTRm). However, use diflunisal only been described small cohort patients with cardiac (CA). We hypothesized that selected ATTR-CA, both wild-type (ATTRwt), would tolerate limited...
Background Light chain ( AL ) and transthyretin ATTR amyloidosis have a similar effect on myocardial function but very different disease trajectories survival. However, limited data are available evaluating subtype‐specific predictors of outcomes in large contemporary cohort. Methods Results We retrospectively investigated 360 patients at the time initial diagnosis cardiac (191 169 from 2002 to 2014. Clinical, laboratory, electrical, morphologic covariates were evaluated based upon amyloid...
Importance Tafamidis reduced all-cause mortality and cardiovascular-related hospitalizations minimized patient-reported health status deterioration at 30 months in patients with transthyretin (ATTR) amyloidosis. However, the clinical significance of changes remains unclear, particularly New York Heart Association (NYHA) class III symptoms who experienced more than those NYHA I-II symptoms. Objective To evaluate taking tafamidis baseline Design, Setting, Participants This randomized trial...
Introduction The 6-minute walk test (6MWT) is used to assess submaximal exercise capacity in clinical trials. Conducting the 6MWT can be challenging when patients cannot visit clinic due physical/travel limitations. This pilot study assessed feasibility of conducting using wearable sensors for with transthyretin amyloid cardiomyopathy.